Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis

Archives of Gynecology and Obstetrics

Volumn 295, Issue 5, 2017, Pages 1079-1087

  Zhao, Mutong ^a   Zhu, Zhiqing ^a   Liu, Chongdong ^a   Zhang, Zhenyu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cutoff; Preeclampsia; Rule in; Rule out; sFlt 1 PlGF

Indexed keywords

ANGIOGENIC FACTOR; PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

BLOOD ANALYSIS; DIAGNOSTIC VALUE; GESTATIONAL AGE; HUMAN; META ANALYSIS; MULTIPLE PREGNANCY; PREECLAMPSIA; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; ADULT; BLOOD; FEMALE; PREGNANCY; REFERENCE VALUE;

ADULT; BIOMARKERS; FEMALE; GESTATIONAL AGE; HUMANS; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 85015665379     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-017-4302-3     Document Type: Review

References (18)

1. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S (2016) Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 374(1):13–22. doi:10.1056/NEJMoa1414838
2. Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, Wieloch P, Semus B, Meloth T, Droge LA, Verlohren S (2016) A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. doi:10.3109/10641955.2016.1141214
3. Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123(24):2856–2869. doi:10.1161/CIRCULATIONAHA.109.853127
4. Villa PM, Hamalainen E, Maki A, Raikkonen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H (2013) Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 13:110. doi:10.1186/1471-2393-13-110
5. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstetr Gynecol 202(2):161, e161–161, e111. doi:10.1016/j.ajog.2009.09.016
6. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C (2010) Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstetr Gynecol 202(1):40 e41–47. doi:10.1016/j.ajog.2009.07.025
7. Stepan H, Unversucht A, Wessel N, Faber R (2007) Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49(4):818–824. doi:10.1161/01.HYP.0000258404.21552.a3
8. Álvarez-Fernández I, Prieto B, Rodríguez V, Ruano Y, Escudero AI, Álvarez FV (2014) New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med (CCLM). doi:10.1515/cclm-2013-0901
9. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H (2014) New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63(2):346–352. doi:10.1161/hypertensionaha.113.01787
10. Andersen LB, Frederiksen-Moller B, Work Havelund K, Dechend R, Jorgensen JS, Jensen BL, Nielsen J, Lykkedegn S, Barington T, Christesen HT (2015) Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. JASH 9(2):86–96. doi:10.1016/j.jash.2014.11.008
11. van Helden J, Weiskirchen R (2015) Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. Clin Biochem 48(16–17):1113–1119. doi:10.1016/j.clinbiochem.2015.06.020
12. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, Fiedler GM, Luthe H, Denk B, Smitz J (2010) Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 43(9):768–770. doi:10.1016/j.clinbiochem.2010.02.010
13. Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H (2015) Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 292(3):507–518. doi:10.1007/s00404-015-3671-8
14. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355(10):992–1005. doi:10.1056/NEJMoa055352
15. Hirashima C, Ohkuchi A, Arai F, Takahashi K, Suzuki H, Watanabe T, Kario K, Matsubara S, Suzuki M (2005) Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res 28(9):727–732. doi:10.1291/hypres.28.727
16. Saito S, Nakashima A (2014) A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. J Reprod Immunol 101–102:80–88. doi:10.1016/j.jri.2013.06.002
17. Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, Taylor RN, Ecker JL, Karumanchi SA, Thadhani R (2005) Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 193(1):16–22. doi:10.1016/j.ajog.2005.03.016
18. Weissgerber TL, Roberts JM, Jeyabalan A, Powers RW, Lee M, Datwyler SA, Gandley RE (2012) Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. Am J Obstetr Gynecol 206(4):358 e310–358. doi:10.1016/j.ajog.2012.01.009